P

Pharmaids Pharmaceuticals Limited

PHARMAID
Market snapshot · 2026-08-11 11:10 UTC

34.00

₹-1.03 (-2.94%)

MARKET CAP

₹119.91 Cr

STOCK P/E

52W HIGH

₹66.00

52W LOW

₹25.60

BOOK VALUE

₹13.44

EPS

₹-3.31

ROE

-22.55%

SECTOR

Health Care

DEBT/EQUITY

49.12

VOLUME

19,203

P/B RATIO

2.53x

PEG RATIO

Sector

Health Care

Themes

Pharmaceuticals
₹62.76₹53.98₹45.19₹36.41₹27.62VolumeAug '25Sep '25Nov '25Jan '26Mar '26Apr '26Jun '26Aug '26

AI Summary

✦ Clartha

Valuation Metrics

Forward Valuation Outlook

Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.

P/S
Undervalued

5Y Average

4.84

Current

4.30

Overvalued

6.63

Undervalued

2.64

P/B
Strongly Undervalued

5Y Average

2.97

Current

2.53

Overvalued

3.41

Undervalued

2.52

Peers & Comparison

No peer data available for this company.
WHY THESE PEERS

No sector data available for this company.

Financials

Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.

Latest revenue

₹2.69 CrMar 2026

Latest net profit

₹-1.31 CrMar 2026

Latest EPS

₹-0.37Mar 2026

Net margin

-40.1%Mar 2026

Performance

Bars show revenue and net profit. The line shows net margin.

Rs crore + margin %
Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26-2200.0%-1650.0%-1100.0%-550.0%0.0%-6.00 Cr-3.00 Cr0.00 Cr3.00 Cr6.00 Cr
  • Revenue
  • Net income
  • Net margin %

Earnings

Revenue is shown in crores. EPS is rupees per share.

Rs crore + Rs/share
Q4 '25Q1 '26Q2 '26Q3 '26Q4 '260.00 Cr2.00 Cr4.00 Cr6.00 Cr8.00 Cr₹-1₹-1₹-1₹-1₹-0
  • Revenue
  • EPS

Revenue to profit conversion

Bridge from operating numbers to profit for the latest reported period.

Rs crore
RevenueExpensesDepreciationOtheradjustmentsOperatingprofitOther incomeInterestOtheradjustmentsProfitbefore taxTax & otherOtheradjustmentsNet Profit-4.00 Cr-2.00 Cr0.00 Cr2.00 Cr4.00 Cr

Latest reported period: Mar 2026

Debt level and coverage

Debt, cash and free cash flow compared on the same crore scale.

Rs crore
Annual view
Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-40 Cr0.00 Cr40 Cr80 Cr120 Cr
  • Debt
  • Free cash flow
  • Cash & equivalents

Results

MetricMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +0.000.000.000.020.010.170.831.210.131.125.970.832.69
Expenses +8.601.611.022.451.811.891.972.942.826.0010.554.503.77
Operating Profit-8.60-1.61-1.02-2.43-1.80-1.72-1.14-1.73-2.69-4.88-4.58-3.67-1.08
OPM %-12,150.00%-18,000.00%-1,011.76%-137.35%-142.98%-2,069.23%-435.71%-76.72%-442.17%-40.15%
Other Income +0.000.41-0.260.760.030.000.010.001.010.353.320.060.04
Interest0.000.000.000.020.290.010.010.072.051.111.020.570.60
Depreciation0.000.010.010.040.050.050.050.050.050.050.060.050.05
Profit before tax-8.60-1.21-1.29-1.73-2.11-1.78-1.19-1.85-3.78-5.69-2.34-4.23-1.69
Tax %-28.37%7.44%-60.47%-33.53%6.16%-8.43%-15.13%-13.51%-19.05%-23.37%-29.06%-26.71%-22.49%
Net Profit +-6.16-1.30-0.50-1.15-2.24-1.62-1.01-1.59-3.06-4.36-1.65-3.11-1.31
EPS in Rs-2.87-0.61-0.23-0.54-0.64-0.46-0.29-0.45-0.87-1.24-0.47-0.88-0.37
Raw PDF

All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).

Shareholding Pattern

HolderJun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters +5.14%32.99%32.99%32.99%32.99%
Public +94.87%67.00%67.01%67.00%67.02%
Others0.01%0.01%
Jun 2026
Promoters +
Public +

Events Timeline

Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended 30Th June 2026.

Aug 06, 2026PDFCompany Reports Open

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Jul 07, 2026PDFCompany Reports Open

Announcement under Regulation 30 (LODR)-Change in Management

Jun 30, 2026PDFCompany Reports Open

Closure of Trading Window

Jun 26, 2026PDFCompany Reports Open

Announcement under Regulation 30 (LODR)-Change in Management

Jun 25, 2026PDFCompany Reports Open